Article Information
vol. 7 no. 1
Published By
Online ISSN
History
- Received July 8, 2020
- Accepted November 17, 2020
- Published online March 22, 2021.
Article Versions
- previous version (December 10, 2020 - 10:02).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©ERS 2021 This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Elisabeth Fenwick1,
- Alan Martin2,
- Melanie Schroeder3,
- Stuart J. Mealing1,
- Oyinkansola Solanke4,
- Nancy Risebrough5 and
- Afisi S. Ismaila6,7⇑
- 1ICON Health Economics, ICON plc., Abingdon, UK
- 2Value Evidence and Outcomes, GlaxoSmithKline plc., Uxbridge, UK
- 3Value Evidence and Outcomes, GlaxoSmithKline plc., Brentford, UK
- 4ICON Health Economics, ICON plc., London, UK
- 5ICON Health Economics, ICON plc., Toronto, ON, Canada
- 6Value Evidence and Outcomes, GlaxoSmithKline plc., Collegeville, PA, USA
- 7Dept of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
- Afisi S. Ismaila, GlaxoSmithKline plc., 1250 South Collegeville Road, Collegeville, PA 19426-0989, USA. E-mail: afisi.s.ismaila{at}gsk.com
Funding
GlaxoSmithKline plc.
Article usage
Altmetrics
Vol 7 Issue 1
Table of Contents
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
